Investment strategy
Four areas where our access, our expertise, and our appetite for early-stage risk actually line up.
We invest in the most promising early-stage companies developing transformative medical technologies, sourced through our national physician network. Our team provides the guidance and support these companies need to reach their full potential.
Our team has extensive experience in medical data science and analytics, which is how we evaluate a technology's real evidence base. We also work with portfolio companies to sharpen their own data strategy and get full value from what they collect.
We invest in companies developing innovative healthcare applications, from medical devices through telemedicine platforms, and we have the expertise to judge whether an application can survive contact with the clinic — and to help bring it to market.
We provide personalized support to our investors, helping them navigate the complexities of private equity investing and stay genuinely informed about what they own.
Invest with confidence
Investing with The Oxford Fund means investing in the future of medicine — but it should never mean investing on faith.
Our team is dedicated to identifying and supporting the most promising early-stage medical technology companies, and our approach is built so that our investors have the information and the support they need to make informed decisions about their capital. Early-stage investing carries real risk, and we would rather an investor understand that clearly than be persuaded past it.
